Use of surrogate outcomes a poor tradeoff for uncertainty in oncology trials

Use of surrogate outcome measures to hasten oncology trials creates a large amount of uncertainty for only an 11-month advantage in bringing a drug into clinical use, a new US study shows. An analysis of trials of 107 cancer drugs approved for 188 indications from 2006 to 2017 found that 38% were approved based on ...

Already a member?

Login to keep reading.

© 2022 the limbic